SAN

75.03

+1.49%↑

ARGX

667.8

-2.57%↓

SHL.DE

34.04

+1.92%↑

FRE

39.47

+1.18%↑

PHIA

22.53

+1.12%↑

SAN

75.03

+1.49%↑

ARGX

667.8

-2.57%↓

SHL.DE

34.04

+1.92%↑

FRE

39.47

+1.18%↑

PHIA

22.53

+1.12%↑

SAN

75.03

+1.49%↑

ARGX

667.8

-2.57%↓

SHL.DE

34.04

+1.92%↑

FRE

39.47

+1.18%↑

PHIA

22.53

+1.12%↑

SAN

75.03

+1.49%↑

ARGX

667.8

-2.57%↓

SHL.DE

34.04

+1.92%↑

FRE

39.47

+1.18%↑

PHIA

22.53

+1.12%↑

SAN

75.03

+1.49%↑

ARGX

667.8

-2.57%↓

SHL.DE

34.04

+1.92%↑

FRE

39.47

+1.18%↑

PHIA

22.53

+1.12%↑

Accueil・Liste d'Actions・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

58.4 -0.17

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

58.05

Max

59.1

Chiffres clés
By Trading Economics
Revenu	-33M 9.5M
Ventes	-66M 152M
P/E Moyenne du Secteur	26.292 51.415
BPA	0.834
Marge bénéficiaire	6.216
Employés	1,950
EBITDA	-45M 18M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+24.85% upside

Dividendes
By Dow Jones
Prochains Résultats	23 juil. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-887M 3.2B
Ouverture précédente	58.57
Clôture précédente	58.4

Sentiment de l'Actualité

By Acuity

50%

157 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

51.1 / N/A Support & Résistance

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mai 2026, 23:10 UTC

Actions en Tendance

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principaux Mouvements du Marché

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Résultats

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Résultats

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Résultats

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Résultats

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Acquisitions, Fusions, Rachats

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Acquisitions, Fusions, Rachats

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Vinci Buys Canada's Modern Group of Companies

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

24.85% hausse

Prévisions sur 12 Mois

Moyen 73.6 EUR 24.85%

Haut 83 EUR

Bas 64.2 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

Achat

Maintien

Vente

Basé sur 2 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

157 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.